Not laid off.
DAMNIT.... seriously? Emily got laid off from her job yesterday. She called me and left me a voicemail while I was at work crying and saying she was scared it was going to happen and it did.
Emily worked with mentally disabled adults, this is a place that's NEEDED, and they are now being forced to cut back thier employees. Fuck this shit, why the hell are we sending millions and millions of dollars to a country that is not owned by the states when people living in THIS one need it. I'm a little annoyed.
She needed that job, she had been looking for a job forever, and i convinced her to get it. She worked there years prior, and really enjoyed her job. What she did was great. She had the mentality of living off of her tax return and state aide for the rest of her life but I convinced her to get back into the real world and make some money to support her kids better. Now she is going to be once again in the situation of either living off of state aide help and unemployment or not getting any help for food/heat etc and busting her ass working a job that will literally give her less money.
I wanna be president, damnit. Not happy today. This is actually making me contemplate moving back to Monroe. Right now I live in Madison, and I bust my chops working and barely being able to afford my own little one room studio. God damnit. Is it really getting to the point where places that are so beneficial and GOOD for just the humane decency of things are getting cut of help? Ridiculous.
Friday, January 29, 2010
Tuesday, January 19, 2010
Another hope.
I randomly look online, well, a lot.. to see if there is any new news articles about Huntingtons disease. Today I found this, it's taken from www.cnnmoney.com and it basically states that there is going to be a lot of money put into drug research for the disease over the course of the next three years. Even if it would be too late to help my sister, which I don't want to even think about, I hope that it will benefit other families someday who are dealing with the same thing. It's pure hell.
The link to the article is.. http://money.cnn.com/news/newsfeeds/articles/globenewswire/181915.htm
Here is the copy/paste of it..
* Strategic alliance with CHDI aimed at accelerating efforts to develop drugs against Huntington's disease * Entails research revenue of up to US$ 37.5 million over the next three years * One of the largest strategic drug discovery alliances within Evotec
HAMBURG, Germany and ABINGDON, UK, Jan. 14, 2010 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today announced the extension of its collaboration with CHDI Foundation, Inc. (CHDI) through to the end of 2012. The collaboration, which is aimed at finding new treatments for Huntington's disease and represents one of the largest joint innovation drug discovery CNS alliances within Evotec, will provide Evotec with up to US$ 37.5 million in research funding over the next three years. Evotec has been providing research and innovation support to CHDI since 2006.
"As a proven leader in the field of drug discovery, Evotec continues to be an important strategic partner in our search for effective treatments for Huntington's disease. Their integrated drug discovery capabilities are helping us advance numerous drug candidates towards the clinic and we look forward to continuing to work with Evotec over the coming years," said Dr. Robert Pacifici, Chief Scientific Officer of CHDI.
The extension of this collaboration is a further validation of Evotec's broad expertise in CNS drug discovery and development. Evotec will provide a full range of neurological research activities and expertise to CHDI, including integrated biology and chemistry supported by compound and library management, target validation, screening, computational chemistry, in vitro and in vivo PK and protein crystallography. Evotec has made a significant investment to put together an integrated platform to provide drug discovery solutions, especially within the area of neuroscience.
Dr. Werner Lanthaler, Chief Executive Officer of Evotec, commented: "We are delighted that CHDI has chosen to further extend our strategic alliance. We view this as an important step in our work with CHDI to develop novel therapies for Huntington's disease and meet this urgent medical need. At the same time it will allow Evotec to gain further experience in defining the underlying mechanisms of other neurodegenerative diseases."
About Huntington's Disease
Huntington's disease is a familial disease caused by a mutation in the huntingtin gene. Each child of a parent with the mutation in the huntingtin gene has a 50-50 chance of inheriting the mutation. As a result of carrying the mutation, an individual's brain cells fail and die leading to cognitive and physical impairments that, over the course of the disease, significantly impair the individual's quality of life and ultimately cause death. Symptoms of Huntington's disease, which generally develop in midlife and become progressively more debilitating as time passes, can also develop in infancy or old age. Once overt symptoms start, patients live for about 15 to 20 years. One person in 10,000 is believed to carry a mutation in the huntingtin gene. There is currently no way to delay the onset of symptoms or slow the progression of Huntington's disease.
About Evotec AG
Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has built substantial drug discovery expertise and an industrialized platform that can drive new innovative small molecule compounds into the clinic. In addition, Evotec has built a deep internal knowledge base in the treatment of diseases related to neuroscience, pain, and inflammation. Leveraging these skills and expertise the Company intends to develop best-in-class differentiated therapeutics and deliver superior science-driven discovery alliances with pharmaceutical and biotechnology companies. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Novartis, Ono Pharmaceutical and Roche. Evotec has product candidates in clinical development and a series of preclinical compounds and development partnerships, including for example a strategic alliance with Roche for the EVT 100 compound family, subtype selective NMDA receptor antagonists for use in treatment-resistant depression. For additional information please go to www.evotec.com.
About CHDI Foundation, Inc.
CHDI is a non-profit organization with a mission to rapidly discover and develop drugs that delay or slow the progression of Huntington's disease. CHDI supports an international network of research laboratories from academia and industry pursuing novel therapies for the treatment of Huntington's disease. As a collaborative enabler, CHDI seeks to bring the right partners together to identify and address critical scientific issues and move drug candidates to clinical evaluation as quickly as possible. More information about CHDI can be found at www.chdifoundation.org.
Forward-looking statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about our expectations and assumptions concerning our strategic collaborations, our regulatory, clinical and business strategies, the progress of our clinical development programmes and management's plans, objectives and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things: risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured; the risk that we will not achieve the anticipated benefits of our collaborations, partnerships and acquisitions in the timeframes expected, or at all; risks relating to our ability to advance the development of product candidates currently in the pipeline or in clinical trials; our inability to further identify, develop and achieve commercial success for new products and technologies; the risk that competing products may be more successful; our inability to interest potential partners in our technologies and products; our inability to achieve commercial success for our products and technologies; our inability to protect our intellectual property and the cost of enforcing or defending our intellectual property rights; our failure to comply with regulations relating to our products and product candidates, including FDA requirements; the risk that the FDA may interpret the results of our studies differently than we have; the risk that clinical trials may not result in marketable products; the risk that we may be unable to successfully secure regulatory approval of and market our drug candidates; and risks of new, changing and competitive technologies and regulations in the U.S. and internationally
The link to the article is.. http://money.cnn.com/news/newsfeeds/articles/globenewswire/181915.htm
Here is the copy/paste of it..
* Strategic alliance with CHDI aimed at accelerating efforts to develop drugs against Huntington's disease * Entails research revenue of up to US$ 37.5 million over the next three years * One of the largest strategic drug discovery alliances within Evotec
HAMBURG, Germany and ABINGDON, UK, Jan. 14, 2010 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today announced the extension of its collaboration with CHDI Foundation, Inc. (CHDI) through to the end of 2012. The collaboration, which is aimed at finding new treatments for Huntington's disease and represents one of the largest joint innovation drug discovery CNS alliances within Evotec, will provide Evotec with up to US$ 37.5 million in research funding over the next three years. Evotec has been providing research and innovation support to CHDI since 2006.
"As a proven leader in the field of drug discovery, Evotec continues to be an important strategic partner in our search for effective treatments for Huntington's disease. Their integrated drug discovery capabilities are helping us advance numerous drug candidates towards the clinic and we look forward to continuing to work with Evotec over the coming years," said Dr. Robert Pacifici, Chief Scientific Officer of CHDI.
The extension of this collaboration is a further validation of Evotec's broad expertise in CNS drug discovery and development. Evotec will provide a full range of neurological research activities and expertise to CHDI, including integrated biology and chemistry supported by compound and library management, target validation, screening, computational chemistry, in vitro and in vivo PK and protein crystallography. Evotec has made a significant investment to put together an integrated platform to provide drug discovery solutions, especially within the area of neuroscience.
Dr. Werner Lanthaler, Chief Executive Officer of Evotec, commented: "We are delighted that CHDI has chosen to further extend our strategic alliance. We view this as an important step in our work with CHDI to develop novel therapies for Huntington's disease and meet this urgent medical need. At the same time it will allow Evotec to gain further experience in defining the underlying mechanisms of other neurodegenerative diseases."
About Huntington's Disease
Huntington's disease is a familial disease caused by a mutation in the huntingtin gene. Each child of a parent with the mutation in the huntingtin gene has a 50-50 chance of inheriting the mutation. As a result of carrying the mutation, an individual's brain cells fail and die leading to cognitive and physical impairments that, over the course of the disease, significantly impair the individual's quality of life and ultimately cause death. Symptoms of Huntington's disease, which generally develop in midlife and become progressively more debilitating as time passes, can also develop in infancy or old age. Once overt symptoms start, patients live for about 15 to 20 years. One person in 10,000 is believed to carry a mutation in the huntingtin gene. There is currently no way to delay the onset of symptoms or slow the progression of Huntington's disease.
About Evotec AG
Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has built substantial drug discovery expertise and an industrialized platform that can drive new innovative small molecule compounds into the clinic. In addition, Evotec has built a deep internal knowledge base in the treatment of diseases related to neuroscience, pain, and inflammation. Leveraging these skills and expertise the Company intends to develop best-in-class differentiated therapeutics and deliver superior science-driven discovery alliances with pharmaceutical and biotechnology companies. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Novartis, Ono Pharmaceutical and Roche. Evotec has product candidates in clinical development and a series of preclinical compounds and development partnerships, including for example a strategic alliance with Roche for the EVT 100 compound family, subtype selective NMDA receptor antagonists for use in treatment-resistant depression. For additional information please go to www.evotec.com.
About CHDI Foundation, Inc.
CHDI is a non-profit organization with a mission to rapidly discover and develop drugs that delay or slow the progression of Huntington's disease. CHDI supports an international network of research laboratories from academia and industry pursuing novel therapies for the treatment of Huntington's disease. As a collaborative enabler, CHDI seeks to bring the right partners together to identify and address critical scientific issues and move drug candidates to clinical evaluation as quickly as possible. More information about CHDI can be found at www.chdifoundation.org.
Forward-looking statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about our expectations and assumptions concerning our strategic collaborations, our regulatory, clinical and business strategies, the progress of our clinical development programmes and management's plans, objectives and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things: risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured; the risk that we will not achieve the anticipated benefits of our collaborations, partnerships and acquisitions in the timeframes expected, or at all; risks relating to our ability to advance the development of product candidates currently in the pipeline or in clinical trials; our inability to further identify, develop and achieve commercial success for new products and technologies; the risk that competing products may be more successful; our inability to interest potential partners in our technologies and products; our inability to achieve commercial success for our products and technologies; our inability to protect our intellectual property and the cost of enforcing or defending our intellectual property rights; our failure to comply with regulations relating to our products and product candidates, including FDA requirements; the risk that the FDA may interpret the results of our studies differently than we have; the risk that clinical trials may not result in marketable products; the risk that we may be unable to successfully secure regulatory approval of and market our drug candidates; and risks of new, changing and competitive technologies and regulations in the U.S. and internationally
Thursday, January 7, 2010
90210
Looking at the title of this post can you take a wild guess what book Em got me for my Christmas present? Yeah. Weirdo.
Christmas with the family rocked, for the first time in years I was able to see my neices and nephews eyes go nuts with every present they ripped open, priceless. Things were a bit different this year with both Grandparents now gone, but the traditional Bystry polish sausage, ham, potatoes and fruit cake that is always ignored were all things I looked forward to.
Since I was in town, Em wanted me to be make-over do-er once again, but suprisingly she didn't need me this time. Before I got back she asked me to lighten her hair more, and I asked her when she wanted me to do it and she said she already did.. it's yellow. It's not blond, it's fricken yellow. Apparantly she likes it, so we just left it at that.
I haven't heard from her for a bit, I have tried to call randomly but she's probably been at work. As far as I know she is still dating 'teenager' (who is now 20 I guess, but the name is going to be there forever.) She's looking forward to meeting "cowboy" too. Yes I've got myself a boyfriend, this shit hasn't happened in years, literally. He's a keeper :)
Hopefully this year brings a bit more joy than the last. Trials and tribulations can make leather skin, but silk is wayyyyyyyyyyy softer.
Here's to a new year.
:)
Christmas with the family rocked, for the first time in years I was able to see my neices and nephews eyes go nuts with every present they ripped open, priceless. Things were a bit different this year with both Grandparents now gone, but the traditional Bystry polish sausage, ham, potatoes and fruit cake that is always ignored were all things I looked forward to.
Since I was in town, Em wanted me to be make-over do-er once again, but suprisingly she didn't need me this time. Before I got back she asked me to lighten her hair more, and I asked her when she wanted me to do it and she said she already did.. it's yellow. It's not blond, it's fricken yellow. Apparantly she likes it, so we just left it at that.
I haven't heard from her for a bit, I have tried to call randomly but she's probably been at work. As far as I know she is still dating 'teenager' (who is now 20 I guess, but the name is going to be there forever.) She's looking forward to meeting "cowboy" too. Yes I've got myself a boyfriend, this shit hasn't happened in years, literally. He's a keeper :)
Hopefully this year brings a bit more joy than the last. Trials and tribulations can make leather skin, but silk is wayyyyyyyyyyy softer.
Here's to a new year.
:)
Subscribe to:
Posts (Atom)
